Assunta
Cirella
Ikertzailea 2024-(e)ra arte
Instituto de Investigación Sanitaria de Navarra
Pamplona, EspañaInstituto de Investigación Sanitaria de Navarra-ko ikertzaileekin lankidetzan egindako argitalpenak (25)
2023
-
CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
Science advances, Vol. 9, Núm. 33, pp. eadf6692
-
Interleukin-18 in cancer immunology and immunotherapy
Expert Opinion on Therapeutic Targets, Vol. 27, Núm. 11, pp. 1035-1042
-
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models
Oncoimmunology, Vol. 12, Núm. 1, pp. 2147317
-
Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis
Journal for immunotherapy of cancer, Vol. 11, Núm. 11
-
Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198
-
Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies
EMBO Molecular Medicine, Vol. 15, Núm. 11
-
Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists
Molecular Therapy - Nucleic Acids, Vol. 33, pp. 668-682
-
Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure
Molecular Therapy - Nucleic Acids, Vol. 33, pp. 599-616
-
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
OncoImmunology, Vol. 12, Núm. 1
-
Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma
Cell Reports Medicine, Vol. 4, Núm. 4
-
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
Cell Reports Medicine, Vol. 4, Núm. 3
2022
-
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β
Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157
-
Advances in mRNA-based drug discovery in cancer immunotherapy
Expert Opinion on Drug Discovery, Vol. 17, Núm. 1, pp. 41-53
-
Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
Cancer research, Vol. 82, Núm. 23, pp. 4373-4385
-
Novel strategies exploiting interleukin-12 in cancer immunotherapy
Pharmacology and Therapeutics, Vol. 239
-
Overcoming the limitations of cytokines to improve cancer therapy
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 107-141
-
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Journal for immunotherapy of cancer, Vol. 10, Núm. 3
-
Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
OncoImmunology, Vol. 11, Núm. 1
2021
-
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26
-
Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils
European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280